Neurobiological Consolidates Phase III Trials To Hasten Viprinex Findings
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
By combining data from two structurally similar Phase III trials, Neurobiological Technologies will hasten the pace at which it can make a definitive call on Viprinex (ancrod) and possibly secure a development partner for the ischemic stroke drug
You may also be interested in...
Viprinex Stroke Trials Get Phase III Nod
Snake venom injection widens ischemic stroke treatment window.
Neurobiological To Revive Viprinex Stroke Trials Following Empire Acquisition
New Phase III trials for Abbott's former anticoagulant will be based on meta-analyses of previous Phase II and III trials of the pit viper venom-derived agent, Neurobiological Technologies says. Empire licensed Viprinex from Abbott in 2002.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.